Humanigen (HGEN)
NASDAQ:HGEN

Humanigen Stock Price & Analysis

383 Followers

HGEN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.13 - $5.95
Previous Close$0.15
Volume993.76K
Average Volume (3M)4.02M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$24.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)>-0.1
Beta1.85
Next EarningsMar 28, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.51
Shares Outstanding119,080,135
R-Squared0.05
Standard Deviation0.32
10 Day Avg. Volume1,211,379
30 Day Avg. Volume4,017,293
Price to Book (P/B)-0.34
Price to Sales (P/S)5.30
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside608.22% Upside
Rating ConsensusHold
Alpha-0.10
Number of Analyst Covering2


Financials


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

HGEN FAQ

What was Humanigen’s price range in the past 12 months?
Humanigen lowest stock price was $0.13 and its highest was $5.95 in the past 12 months.
    What is Humanigen’s market cap?
    Currently, no data Available
    When is Humanigen’s upcoming earnings report date?
    Humanigen’s upcoming earnings report date is Mar 28, 2023 which is in 112 days.
      How were Humanigen’s earnings last quarter?
      Humanigen released its earnings results on Nov 17, 2022. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.181 by -$0.049.
        Is Humanigen overvalued?
        According to Wall Street analysts Humanigen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Humanigen pay dividends?
          Humanigen does not currently pay dividends.
          What is Humanigen’s EPS estimate?
          Humanigen’s EPS estimate is -$0.13.
            How many shares outstanding does Humanigen have?
            Humanigen has 119,080,130 shares outstanding.
              What happened to Humanigen’s price movement after its last earnings report?
              Humanigen reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.181. Following the earnings report the stock price went down -5.882%.
                Which hedge fund is a major shareholder of Humanigen?
                Among the largest hedge funds holding Humanigen’s share is Graham Capital Management, L.P.. It holds Humanigen’s shares valued at N/A.

                  ---

                  Humanigen Stock Smart Score

                  N/A
                  Not Ranked
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -97.52%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  Trailing 12-Months
                  Asset Growth
                  -66.68%
                  Trailing 12-Months
                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Humanigen

                  Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the developing next-generation cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Cellectar Biosciences
                  180 Life Sciences
                  eFFECTOR Therapeutics
                  Immix Biopharma, Inc.

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis